Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Terns Pharmaceuticals (TERN) Non-Current Assets (2020 - 2025)

Terns Pharmaceuticals filings provide 6 years of Non-Current Assets readings, the most recent being $884000.0 for Q4 2025.

  • Quarterly Non-Current Assets fell 51.43% to $884000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $5.3 million through Dec 2025, up 4.15% year-over-year, with the annual reading at $884000.0 for FY2025, 51.43% down from the prior year.
  • Non-Current Assets hit $884000.0 in Q4 2025 for Terns Pharmaceuticals, down from $1.4 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $2.6 million in Q1 2022 and bottomed at $642000.0 in Q2 2024.
  • Average Non-Current Assets over 5 years is $1.4 million, with a median of $1.4 million recorded in 2023.
  • The largest annual shift saw Non-Current Assets tumbled 53.55% in 2024 before it skyrocketed 127.88% in 2025.
  • Terns Pharmaceuticals' Non-Current Assets stood at $1.1 million in 2021, then surged by 61.49% to $1.8 million in 2022, then plummeted by 41.06% to $1.1 million in 2023, then skyrocketed by 67.74% to $1.8 million in 2024, then tumbled by 51.43% to $884000.0 in 2025.
  • Per Business Quant, the three most recent readings for TERN's Non-Current Assets are $884000.0 (Q4 2025), $1.4 million (Q3 2025), and $1.5 million (Q2 2025).